Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Clover And 2 Other ASX Penny Stocks To Consider

In This Article:

The Australian market has shown resilience, with the ASX200 rising by 0.75% to 8,437 points, buoyed by positive developments such as China's measured response to tariffs and strong performances in the materials sector. In such a climate, investors often look beyond blue-chip stocks for opportunities that offer both growth and value potential. Penny stocks, though sometimes seen as a throwback to earlier trading days, remain relevant for those seeking companies with solid financials and hidden potential.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.79

A$141.28M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.575

A$66.82M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.50

A$310.07M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.90

A$106.21M

★★★★★★

GTN (ASX:GTN)

A$0.535

A$105.06M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.94

A$322.38M

★★★★★★

SHAPE Australia (ASX:SHA)

A$3.00

A$247.9M

★★★★★★

IVE Group (ASX:IGL)

A$2.20

A$334.56M

★★★★☆☆

SKS Technologies Group (ASX:SKS)

A$1.59

A$235.35M

★★★★★★

Nickel Industries (ASX:NIC)

A$0.745

A$3.2B

★★★★★☆

Click here to see the full list of 1,032 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Clover

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Clover Corporation Limited produces, refines, and sells natural oils and encapsulated powders across Australia, New Zealand, Asia, Europe, the Middle East, and the Americas with a market cap of A$70.97 million.

Operations: The company generates revenue of A$62.21 million from its Nutritional Oil and Microencapsulated Powders segment.

Market Cap: A$70.97M

Clover Corporation Limited, with a market cap of A$70.97 million, operates in the nutritional oil and encapsulated powders segment, generating A$62.21 million in revenue. Despite its experienced management team and board, Clover has faced challenges with negative earnings growth over the past year (-75.6%) and declining profits over five years (24.1% annually). However, it maintains strong financial health with more cash than total debt and well-covered interest payments by EBIT (3.5x coverage). The company's short-term assets significantly exceed both short-term and long-term liabilities, providing a solid liquidity position despite low profit margins (2.4%).

ASX:CLV Debt to Equity History and Analysis as at Feb 2025
ASX:CLV Debt to Equity History and Analysis as at Feb 2025

First Graphene

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: First Graphene Limited focuses on the research, development, mining, exploration, manufacture, and sale of graphene products in Australia and the United Kingdom with a market cap of A$41.54 million.